| Paul Jackson, MD | |
|
795 El Camino Real, Palo Alto, CA 94301-2302 | |
| (650) 321-4121 | |
| (650) 853-4765 |
| Full Name | Paul Jackson |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 28 Years |
| Location | 795 El Camino Real, Palo Alto, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770651291 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | G85830 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sequoia Hospital | Redwood city, CA | Hospital |
| Peninsula Medical Center | Burlingame, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sutter Bay Medical Foundation | 4284538778 | 2941 |
News Archive
BD (Becton, Dickinson and Company), a leading global medical technology company, today reported quarterly revenues of $2.157 billion for the third fiscal quarter ended June 30, 2014, representing an increase of 5.1 percent from the prior-year period, or 4.6 percent on a foreign currency-neutral basis.
Amphetamines, including the drug popularly known as Ecstasy, can reverse the symptoms of Parkinson's disease in mice with an acute form of the condition, according to new research at Duke University Medical Center.
Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation and biosuperior antibodies, announced today that it has licensed its XmAb® and Xtend™ technology platforms to Centocor Research & Development, Inc. for the optimization of Centocor's antibody drug candidates.
Among patients with cutaneous melanoma who had brain metastases (MBM), first-line treatment with a checkpoint inhibitor was associated with a 1.4-fold increase in median overall survival, according to results from a national cohort.
› Verified 6 days ago
| Entity Name | Sutter Bay Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013950807 PECOS PAC ID: 4284538778 Enrollment ID: O20031125000909 |
News Archive
BD (Becton, Dickinson and Company), a leading global medical technology company, today reported quarterly revenues of $2.157 billion for the third fiscal quarter ended June 30, 2014, representing an increase of 5.1 percent from the prior-year period, or 4.6 percent on a foreign currency-neutral basis.
Amphetamines, including the drug popularly known as Ecstasy, can reverse the symptoms of Parkinson's disease in mice with an acute form of the condition, according to new research at Duke University Medical Center.
Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation and biosuperior antibodies, announced today that it has licensed its XmAb® and Xtend™ technology platforms to Centocor Research & Development, Inc. for the optimization of Centocor's antibody drug candidates.
Among patients with cutaneous melanoma who had brain metastases (MBM), first-line treatment with a checkpoint inhibitor was associated with a 1.4-fold increase in median overall survival, according to results from a national cohort.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Paul Jackson, MD 325 Distel Cir, Los Altos, CA 94022-1408 Ph: (650) 853-2919 | Paul Jackson, MD 795 El Camino Real, Palo Alto, CA 94301-2302 Ph: (650) 321-4121 |
News Archive
BD (Becton, Dickinson and Company), a leading global medical technology company, today reported quarterly revenues of $2.157 billion for the third fiscal quarter ended June 30, 2014, representing an increase of 5.1 percent from the prior-year period, or 4.6 percent on a foreign currency-neutral basis.
Amphetamines, including the drug popularly known as Ecstasy, can reverse the symptoms of Parkinson's disease in mice with an acute form of the condition, according to new research at Duke University Medical Center.
Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation and biosuperior antibodies, announced today that it has licensed its XmAb® and Xtend™ technology platforms to Centocor Research & Development, Inc. for the optimization of Centocor's antibody drug candidates.
Among patients with cutaneous melanoma who had brain metastases (MBM), first-line treatment with a checkpoint inhibitor was associated with a 1.4-fold increase in median overall survival, according to results from a national cohort.
› Verified 6 days ago
Gary Kenneth Steinberg, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Palo Alto, CA 94305 Phone: 650-723-4000 | |
Cormac Oliver Loughrey Maher, MD Neurological Surgery Medicare: Medicare Enrolled Practice Location: 725 Welch Rd, Palo Alto, CA 94304 Phone: 650-497-8000 | |
Dr. Tim E. Darsaut, M.D., MSC., FRCS(C) Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 1237 Clark Way, Palo Alto, CA 94304 Phone: 780-232-7745 | |
Natalie Rw Limoges, DO Neurological Surgery Medicare: Medicare Enrolled Practice Location: 725 Welch Rd, Palo Alto, CA 94304 Phone: 650-497-8000 | |
Linden Elizabeth Fornoff, M.D. Neurological Surgery Medicare: Medicare Enrolled Practice Location: 730 Welch Rd, Palo Alto, CA 94304 Phone: 650-497-8000 | |
Thomas Joseph Wilson, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Palo Alto, CA 94304 Phone: 650-723-4000 | |
Corinna Clio Zygourakis, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Palo Alto, CA 94304 Phone: 650-723-4000 |